AR004675A1 - Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas. - Google Patents

Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas.

Info

Publication number
AR004675A1
AR004675A1 ARP960103850A AR10385096A AR004675A1 AR 004675 A1 AR004675 A1 AR 004675A1 AR P960103850 A ARP960103850 A AR P960103850A AR 10385096 A AR10385096 A AR 10385096A AR 004675 A1 AR004675 A1 AR 004675A1
Authority
AR
Argentina
Prior art keywords
preparing
pharmaceutical compositions
procedure
compounds
cor6
Prior art date
Application number
ARP960103850A
Other languages
English (en)
Original Assignee
Merck Patent Ges Mit Beschränkter Haftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Ges Mit Beschränkter Haftung filed Critical Merck Patent Ges Mit Beschränkter Haftung
Publication of AR004675A1 publication Critical patent/AR004675A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)

Abstract

Nuevos compuestos antagonistas de receptores de endotelina de fórmula (I), en la que -Y-Z- es -NR7-CO,-N=C(OR79- ó N-CR8-; R1 es -NR7-CO, -N=C(OR7)-,-N=C(OR7)- ó -N=CR8; R1 es Ar; R2 es COR6, (CH2)nCOOR6, CN, 1H-tetrazol-5-ilo ó CONHSO2Ar; R1,R4,R5 independientemente representan R6, OR6, S(O)mR6, Hal,NO2, NR6R6, NHCOR6, NHSO2R6, OCOR6, COR6 ó CN, donde R1 y R4 pueden representar, en conjunto, también un grupo O(CH2)nO; R6, R6 independientementeson H, alquilo de 1 a 6 átomos decarb ono, bencilo o fenilo, R7 es (CH2nAr, R8 es Ar ó OAr; Ar es un fenilo no sustituido o sustituido una, dos o tres vecescon R9, R10 ó R11 o un naftilo no sustituido o un grupo (II) no sustituido o sustituido una o dos veces el fenilo con R9 óR10 ó un grupo (III) nosustituido o sustituido una o dos veces en el ciclohexadienilo con R9 ó R10; R9, R10, R11 independientemente son R6, OR6, Hal, CF3, OCF3, OCHF2, OCH2F, NO2,NR6R6, NHCOR6, CN, NHSO2R6, COOR6, COR6, CONHSO2Ar, O(CH2)NR2,O(CH2)NOR6 ó S8o)nR6; E es CH2, S ú O, D es carbonilo ó [C(R6R6)]n, Hal es F, Cl, Br ó I; Xes O ó S;m es 0, 1 ó 2;n es 1 ó 2; y las sales de estos compuestos. También se refiere a unprocedimiento para preparar dichos compuestos, acomposicionesfarmacéutica s que los contienen, y a un procedimiento para la elaboración de dichas composiciones.
ARP960103850A 1995-08-02 1996-08-02 Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas. AR004675A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19528418A DE19528418A1 (de) 1995-08-02 1995-08-02 Endothelin-Rezeptor-Antagonisten

Publications (1)

Publication Number Publication Date
AR004675A1 true AR004675A1 (es) 1999-03-10

Family

ID=7768528

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP960103850A AR004675A1 (es) 1995-08-02 1996-08-02 Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas.

Country Status (16)

Country Link
US (1) US5731321A (es)
EP (1) EP0757039A1 (es)
JP (1) JPH0940649A (es)
KR (1) KR970010746A (es)
AR (1) AR004675A1 (es)
AU (1) AU705959B2 (es)
BR (1) BR9603252A (es)
CA (1) CA2182469A1 (es)
CZ (1) CZ224096A3 (es)
DE (1) DE19528418A1 (es)
HU (1) HUP9602127A1 (es)
MX (1) MX9603199A (es)
NO (1) NO963213L (es)
PL (1) PL315479A1 (es)
SK (1) SK100296A3 (es)
ZA (1) ZA966552B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0815870A3 (en) * 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
DE19839499A1 (de) * 1998-08-29 2000-03-02 Merck Patent Gmbh 2-Oxo-2H-chinolinderivate
DE10155076A1 (de) * 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
JP4794445B2 (ja) * 2003-09-23 2011-10-19 メルク・シャープ・エンド・ドーム・コーポレイション キノリンカリウムチャネル阻害剤
US7939545B2 (en) * 2006-05-16 2011-05-10 Boehringer Ingelheim International Gmbh Inhibitors of human immunodeficiency virus replication
JP5634263B2 (ja) * 2007-08-16 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング キナゾリンジオンキマーゼ阻害剤
SI2220076T1 (sl) * 2007-11-15 2012-05-31 Gilead Sciences Inc Inhibitorji replikacije virusa humane imunske pomankljivosti
EA201200631A1 (ru) 2007-11-16 2012-11-30 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336714C (en) * 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
GB9115153D0 (en) * 1991-07-12 1991-08-28 Patel Bipin C M Sol-gel composition for producing glassy coatings
DE4208304A1 (de) * 1992-03-16 1993-09-23 Merck Patent Gmbh 2-oxochinolinderivate
US5565472A (en) * 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
ZA939516B (en) * 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
EP0617001B1 (en) * 1993-03-19 2000-01-26 Merck & Co. Inc. Phenoxyphenylacetic acid derivatives
JPH06340658A (ja) * 1993-04-08 1994-12-13 Kyowa Hakko Kogyo Co Ltd ベンゾイミダゾール誘導体
US5817653A (en) * 1993-08-06 1998-10-06 Smithkline Beecham Corporation Endothelin receptor antagonists
DE4341663A1 (de) * 1993-12-07 1995-06-08 Basf Ag Anellierte 2-Oxopiperazine, ihre Herstellung und Verwendung

Also Published As

Publication number Publication date
AU705959B2 (en) 1999-06-03
DE19528418A1 (de) 1997-02-06
HUP9602127A1 (hu) 1998-05-28
MX9603199A (es) 1997-07-31
JPH0940649A (ja) 1997-02-10
ZA966552B (en) 1997-02-18
BR9603252A (pt) 1998-04-28
HU9602127D0 (en) 1996-09-30
US5731321A (en) 1998-03-24
NO963213D0 (no) 1996-08-01
KR970010746A (ko) 1997-03-27
CZ224096A3 (en) 1997-02-12
PL315479A1 (en) 1997-02-03
EP0757039A1 (de) 1997-02-05
AU6079296A (en) 1997-02-06
NO963213L (no) 1997-02-03
CA2182469A1 (en) 1997-02-03
SK100296A3 (en) 1997-03-05

Similar Documents

Publication Publication Date Title
NZ511739A (en) New esters derived from substituted phenyl-cyclohexyl compounds
AR008377A1 (es) Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto
AR033306A1 (es) Compuestos
AR037882A1 (es) Cis-imidazolinas
AR007077A1 (es) Derivados tetrahidroisoquinolina, un procedimiento para su preparacion, una composicion farmaceutica que los contiene, el uso de los mismos parala fabricacion de un medicamento
PT96890A (pt) Processo para a preparacao de novos derivados com estrutura naftalenica e de composicoes farmaceuticas que os contem
CO5021213A1 (es) INHIBIDORES DE FACTOR DE TRANSCRIPCION NF-k8
CO5690588A2 (es) Derivados de 4-tetrazolilo-4 fenilpiperidina para el trata- miento del dolor
AR050261A2 (es) Aminoacidos con afinidad por la proteina alfa-2-delta y composiciones farmaceuticas que los contienen y su uso para preparar un medicamento
FI961300A0 (fi) Hydroksisubstituoituja atsetidinoniyhdisteitä, jotka ovat käyttökelpoisia hypokolesterolemisia yhdisteitä
AR004706A1 (es) Un compuesto derivado de benzoxazina y pirido-oxazina utiles como antimicrobianos, composicion farmaceutica que lo contienen, un metodo para preparar dichos compuestos e intermediarios utiles para dicho metodo.
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
ECSP034660A (es) Derivados del novedoso carbamato de quinuclidina y las composiciones medicinales que los contienen
ATE369855T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren
PE20212302A1 (es) Inhibidores de apol1 y sus metodos de uso
AR007759A1 (es) Nuevos compuestos heterociclicos, el uso de los mismos para preparar composiciones farmaceuticas, un procedimiento para su preparacion ycomposiciones farmaceuticas que los comprenden.
BR9307580A (pt) Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano
CO5280081A1 (es) Antibacterianos de piperidiniloxi oxazolidinona, composicion farmaceutica que los comprende y proceso para su preparacion
CO5200758A1 (es) Derivados de 1,5-dihidropirrol-2-ona sustituida, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estos compuestos para la preparacion de medicamentos
AR004675A1 (es) Nuevos compuestos antagonistas de receptores de endotelina, procedimiento para prepararlos, composiciones farmaceuticas que los contienen yprocedimiento para preparar estas composiciones farmaceuticas.
AR010809A1 (es) Compuestos derivados de aminofosfonatos, un procedimiento para su preparacion, composicion farmaceutica que los comprenden, uso de los mismospara la fabricacion de un medicamento util en el tratamiento de arterioesclerosis
PE20001339A1 (es) Uso de derivados del acido 4-biarilbutirico y 5-biarilpentanoico sustituidos como inhibidores de la metaloproteasa de matriz para el tratamiento de enfermedades respiratorias
PE27497A1 (es) Derivados de 1,5 benzodiazepina
AR023111A1 (es) Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden
UY28688A1 (es) Derivados de amida